Clinical trials: Clonal Hematopoiesis of Indeterminate Potential
Systemic Lupus Erythematosus
Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Accelerated atherosclerosis in patients with systemic lupus erythematosus (SLE) is not fully explained by Framingham risk factors.
- Trial name
- HEMATOPLUS (NCT05146414)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ACS, Clonal Hematopoiesis of Indeterminate Potential
CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation
In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete…
- Conditions
- ACS, Clonal Hematopoiesis of Indeterminate Potential, Smoking Cessation
- Trial name
- CHIP-RETENTION (NCT04987268)
- Testing
- clonal hematopoiesis of indeterminate potential
- Where
- China
- Volunteers
- 1,029 people
- Sponsor
- Shenyang Northern Hospital
Venous Thromboses, Thromboembolic Disease
Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative…
- Conditions
- Venous Thromboses, Thromboembolic Disease, Neutrophil Extracellular Trap Formation, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- CLODETTE (NCT05711173)
- Testing
- Additional blood sampling
- Where
- 7 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Bordeaux